Canaccord raised the firm’s price target on Verve Therapeutics (VERV) to $39 from $32 and keeps a Buy rating on the shares. The firm said Verve’s initial Ph1b data for VERVE-102 knocked it out of the park on both safety and efficacy and accomplished everything it sought to do, and more. Canaccord increased our POS for the program from 50% to 70% and noted the company will report updated data including higher dose data, at a major medical meeting in 2H25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- Verve Therapeutics price target raised to $25 from $15 at H.C. Wainwright
- Buy Rating for Verve Therapeutics: Promising Safety and Efficacy of VERVE-102 in Phase 1b Heart-2 Study
- Verve announces initial data from Heart-2 Phase 1b trial of VERVE-102
- Verve Therapeutics receives FDA Fast Track designation for VERVE-102